Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Achillion Pharmaceuticals, Inc. (NQ: ACHN)
7.600 USD  -0.170 (-2.19%)
Streaming Delayed Price  /  Updated: 1:21 PM EDT, May 20, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Achillion Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 Next >
Long-Term Positives En-Route, Review of Healthcare Reform - Equity Research on Achillion Pharmaceuticals, Inc. and Health Management Associates, Inc.
July 22, 2011
from Marketwired News Releases
Achillion Announces Initiation of Phase 1 Trial of ACH-2928 for the Treatment of Hepatitis C
July 11, 2011
First-in-Human Trial to Evaluate Safety and Tolerability of First Generation NS5A Inhibitor in Both Healthy Subjects and Genotype 1 HCV-Infected Patients Read More
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Closing of Public Offering and Exercise of Overallotment Option
June 27, 2011
from GlobeNewswire News Releases
Achillion Pharmaceuticals Leads MicroStockProfit.com Stock Watchlist
June 23, 2011
from GlobeNewswire News Releases
Wednesday's HealthCare Sector Gainers (ACHN, LMNX, GERN) & Losers (NUVA, INHX, SNMX) by Stockmister.com
June 23, 2011
from EmailWire.Com Press Releases
Achillion Initiates 12-Week Dosing in Phase 2 Trial of ACH-1625 for the Treatment of Chronic Hepatitis C
June 22, 2011
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
June 22, 2011
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 20, 2011
from GlobeNewswire News Releases
Achillion Announces Initiation of Phase 1 Trial of ACH-2684 for the Treatment of Hepatitis C
May 25, 2011
First-in-Human Trial Will Evaluate Safety of Pan-Genotypic Protease Inhibitor in Both Healthy Subjects and Genotype 1 or 3 HCV-Infected Patients Read More
from GlobeNewswire News Releases
Achillion to Present at Two Upcoming Investor Conferences
May 20, 2011
from GlobeNewswire News Releases
Achillion Added to the NASDAQ Biotechnology Index (NBI)
May 18, 2011
from GlobeNewswire News Releases
Achillion Reports First Quarter 2011 Financial Results
May 04, 2011
from GlobeNewswire News Releases
Achillion to Present at Upcoming Investor Conferences
April 08, 2011
from GlobeNewswire News Releases
Achillion Announces Positive RVR Results With ACH-1625 to Treat Chronic Hepatitis C
March 30, 2011
Once-Daily Dose Achieves 75 - 81% RVR in a Well Tolerated Combination Regimen Read More
from GlobeNewswire News Releases
Achillion Granted U.S. Patent for ACH-1625 and Related Protease Inhibitors
March 16, 2011
from GlobeNewswire News Releases
Achillion Reports 2010 Fourth Quarter and Year-End Financial Results
March 02, 2011
from GlobeNewswire News Releases
Achillion to Present at Upcoming Investor Conferences
February 09, 2011
from GlobeNewswire News Releases
INTT, THLD, MTSL, PSID, ACHN: Biotech Companies Rule the Volatility Field
February 09, 2011
from EmailWire.Com Press Releases
Mega Stock Picks Initiates Coverage on GenVec Inc. (GNVC)
January 13, 2011
from EmailWire.Com Press Releases
Penny Stock Fever Initiates Coverage on GenVec Inc. (GNVC)
January 06, 2011
from EmailWire.Com Press Releases
Achillion to Present Data From Studies of ACH-1625 in Hepatitis C at Asian Pacific Liver Conference
December 06, 2010
from GlobeNewswire News Releases
Achillion Awarded $2.0 Million in Qualified Therapeutic Discovery Project Grants
November 04, 2010
from GlobeNewswire News Releases
Achillion Reports Third Quarter and Nine Month Financial Results
October 27, 2010
from GlobeNewswire News Releases
Achillion Announces Executive Promotions
October 20, 2010
from GlobeNewswire News Releases
Achillion Announces Dosing of First Patient in Phase II Trial of ACH-1625 for the Treatment of Hepatitis C
September 30, 2010
from GlobeNewswire News Releases
Achillion to Present Multiple Posters at AASLD's The Liver Meeting 2010
September 15, 2010
from GlobeNewswire News Releases
Achillion Announces Private Placement of $50 Million
August 18, 2010
from GlobeNewswire News Releases
Achillion Reports Second Quarter and Six Month Financial Results
August 13, 2010
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Nomination of NS5A Inhibitor as a Lead Clinical Candidate for Treatment ff HCV
July 22, 2010
ACH-2928 Demonstrates Excellent Potency Against HCV RNA Replication, Holds Potential for Combination Therapy Read More
from GlobeNewswire News Releases
Achillion to Present at Upcoming Conference
June 03, 2010
from GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here